January 24, 2011 – Lantheus Medical Imaging has entered into a contract with Novation for Ablavar (gadofosveset trisodium) and Definity Vial for Injectable Suspension (Perflutren Lipid Microsphere). The agreement will provide increased access to the diagnostic imaging agents for healthcare providers served by Novation.
Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), and 5,500 members of Provista, LLC, representing 28,000 sites.
Ablavar is a magnetic resonance angiography (MRA) blood pool imaging agent indicated for evaluation of aortoiliac disease (AIOD) in adults with known or suspected peripheral vascular disease. Definity is used in patients with suboptimal echocardiograms to opacify the left ventricle chamber and to improve the delineation of the left ventricular endocardial border.
Diagnostic imaging agents can help physicians in the diagnosis and treatment of disease by improving image quality. These agents are used to improve image quality. Ablavar lets physicians detect vascular disease using MRA, which is less invasive than conventional X-ray angiography and avoids exposing patients to ionizing radiation.
For more information: www.lantheus.com, www.novationco.com